Limits...
Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.

Poon K, King AB - Drug Healthc Patient Saf (2010)

Bottom Line: Basal insulins have been continually improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hagedorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a longer duration of action.Overall, glargine and detemir do not differ greatly in their safety and efficacy profiles.Major differences between the two include lower within-subject variability, lower risk of hypoglycemia, and a weight-sparing effect with insulin detemir.

View Article: PubMed Central - PubMed

Affiliation: Diabetes Care Center, Salinas, CA, USA.

ABSTRACT
Diabetes mellitus is a growing public health concern in the US and worldwide. Insulin therapy is the cornerstone of diabetes therapy, and the use of basal insulins will increase as clinicians strive to help their patients reach glycemic goals. Basal insulins have been continually improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hagedorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a longer duration of action. Overall, glargine and detemir do not differ greatly in their safety and efficacy profiles. Major differences between the two include lower within-subject variability, lower risk of hypoglycemia, and a weight-sparing effect with insulin detemir. This review summarizes data from the key pharmacokinetic and pharmacodynamic studies, as well as clinical and observational studies to elucidate the role of each basal insulin analog in therapy.

No MeSH data available.


Related in: MedlinePlus

Pharmacodynamic profile of insulin detemir.Duration of action, time to peak action (GIRmax), and overall effect (AUCGIR/100). Data obtained from Plank et al.20
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108694&req=5

f2-dhps-2-213: Pharmacodynamic profile of insulin detemir.Duration of action, time to peak action (GIRmax), and overall effect (AUCGIR/100). Data obtained from Plank et al.20

Mentions: Plank et al24 also found a dose-dependent duration of action for insulin detemir in type 1 diabetes from 5.2 hours at the lowest dose of 0.1 U/kg to 23.2 hours at the highest dose of 1.6 U/kg and a flat and protracted pharmacodynamic profile (Figure 2). Limitations of this study include it being a first-dose study and not a steady-state study.


Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.

Poon K, King AB - Drug Healthc Patient Saf (2010)

Pharmacodynamic profile of insulin detemir.Duration of action, time to peak action (GIRmax), and overall effect (AUCGIR/100). Data obtained from Plank et al.20
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108694&req=5

f2-dhps-2-213: Pharmacodynamic profile of insulin detemir.Duration of action, time to peak action (GIRmax), and overall effect (AUCGIR/100). Data obtained from Plank et al.20
Mentions: Plank et al24 also found a dose-dependent duration of action for insulin detemir in type 1 diabetes from 5.2 hours at the lowest dose of 0.1 U/kg to 23.2 hours at the highest dose of 1.6 U/kg and a flat and protracted pharmacodynamic profile (Figure 2). Limitations of this study include it being a first-dose study and not a steady-state study.

Bottom Line: Basal insulins have been continually improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hagedorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a longer duration of action.Overall, glargine and detemir do not differ greatly in their safety and efficacy profiles.Major differences between the two include lower within-subject variability, lower risk of hypoglycemia, and a weight-sparing effect with insulin detemir.

View Article: PubMed Central - PubMed

Affiliation: Diabetes Care Center, Salinas, CA, USA.

ABSTRACT
Diabetes mellitus is a growing public health concern in the US and worldwide. Insulin therapy is the cornerstone of diabetes therapy, and the use of basal insulins will increase as clinicians strive to help their patients reach glycemic goals. Basal insulins have been continually improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hagedorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a longer duration of action. Overall, glargine and detemir do not differ greatly in their safety and efficacy profiles. Major differences between the two include lower within-subject variability, lower risk of hypoglycemia, and a weight-sparing effect with insulin detemir. This review summarizes data from the key pharmacokinetic and pharmacodynamic studies, as well as clinical and observational studies to elucidate the role of each basal insulin analog in therapy.

No MeSH data available.


Related in: MedlinePlus